Biosimilars Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022 - 2028

Biosimilars Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022 - 2028

Biosimilars are biopharmaceutical drugs that have active components and are similar to the drugs, which have been previously licensed. They are identical copies of the original product and can be manufactured only when the patent for the original innovator product expires. Biosimilars are majorly used in therapeutic applications for the treatment of various types of cancer and non-communicable diseases (asthma and arthritis).
Increasing prevalence of cancer is expected to boost growth of the biosimilars market. For instance, according to National Institute of Cancer Prevention and Research (NICPR), in 2018, 1,62,468 new cases and 87,090 deaths were reported due to breast cancer in India. Biosimilars are designed to be highly similar to originator biologic products, which represents an opportunity to increase access and reduce costs for patients and healthcare systems.
Market Dynamics
Increasing number of biosimilar approvals in clinical management of various diseases such as diabetes and hormonal imbalance is expected to drive growth of the biosimilars market. According to the Generics and Biosimilars Initiative (GABI) 2021 report, around 40 different biosimilars were approved in Europe, covering several different therapeutic classes: granulocyte colony-stimulating factors, and erythropoiesis-stimulating agents (ESAs), among others.
Moreover, increasing research and development in biosimilars, robust biosimilar pipeline portfolio, and support from healthcare regulatory bodies in fast lining biosimilar approvals are some of the major factors that are expected to drive growth of the market. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) both provide guidance for the development of biosimilar drugs. However, stringent regulatory guidelines for development and manufacturing of biosimilars and fragile process of biosimilars production are expected to negatively impact growth of the global biosimilars market.
Key features of the study:
This report provides in-depth analysis of the biosimilars market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global biosimilars market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co., Ltd., Biocon Limited, Amgen, Inc., Dr. Reddy's Laboratories, and Sanofi S.A.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, government initiatives, technological up-gradation, market expansion, and marketing tactics
The global biosimilars market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for biosimilars market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:
Global Biosimilars Market, By Drug Class:
Recombinant Human Growth Hormone
Granulocyte Colony-Stimulating Factor
Insulin
Anticoagulants
Fusion Proteins
Erythropoietin
Monoclonal Antibodies
Follitropin
Others
Global Biosimilars Market, By Therapy Type:
Oncology
Immunology
Hematology
Hormone Therapy
Metabolic Disorders
Others
Global Biosimilars Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Specialty Pharmacies
Global Biosimilars Market, By Region:
North America
By Country:
U.S.
Canada
By Drug Class:
Recombinant Human Growth Hormone
Granulocyte Colony-Stimulating Factor
Insulin
Anticoagulants
Fusion Proteins
Erythropoietin
Monoclonal Antibodies
Follitropin
Others
By Therapy Type:
Oncology
Immunology
Hematology
Hormone Therapy
Metabolic Disorders
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Specialty Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Class:
Recombinant Human Growth Hormone
Granulocyte Colony-Stimulating Factor
Insulin
Anticoagulants
Fusion Proteins
Erythropoietin
Monoclonal Antibodies
Follitropin
Others
By Therapy Type:
Oncology
Immunology
Hematology
Hormone Therapy
Metabolic Disorders
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Specialty Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Class:
Recombinant Human Growth Hormone
Granulocyte Colony-Stimulating Factor
Insulin
Anticoagulants
Fusion Proteins
Erythropoietin
Monoclonal Antibodies
Follitropin
Others
By Therapy Type:
Oncology
Immunology
Hematology
Hormone Therapy
Metabolic Disorders
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Specialty Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Class:
Recombinant Human Growth Hormone
Granulocyte Colony-Stimulating Factor
Insulin
Anticoagulants
Fusion Proteins
Erythropoietin
Monoclonal Antibodies
Follitropin
Others
By Therapy Type:
Oncology
Immunology
Hematology
Hormone Therapy
Metabolic Disorders
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Specialty Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug Class:
Recombinant Human Growth Hormone
Granulocyte Colony-Stimulating Factor
Insulin
Anticoagulants
Fusion Proteins
Erythropoietin
Monoclonal Antibodies
Follitropin
Others
By Therapy Type:
Oncology
Immunology
Hematology
Hormone Therapy
Metabolic Disorders
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Specialty Pharmacies
Africa
By Country:
South Africa
Central Africa
North Africa
By Drug Class:
Recombinant Human Growth Hormone
Granulocyte Colony-Stimulating Factor
Insulin
Anticoagulants
Fusion Proteins
Erythropoietin
Monoclonal Antibodies
Follitropin
Others
By Therapy Type:
Oncology
Immunology
Hematology
Hormone Therapy
Metabolic Disorders
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Specialty Pharmacies
Company Profiles
Novartis AG *
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Pfizer, Inc.
Teva Pharmaceutical Industries Ltd.
Celltrion Healthcare Co., Ltd.
Biocon Limited
Amgen, Inc.
Dr. Reddy's Laboratories
Sanofi S.A.
“*” marked represents similar segmentation in other categories in the respective section.